Navigation Links
Advances reported in quest for drugs targeting childhood cancer
Date:3/29/2010

Investigators believe they have identified the founding member of a chemical family they hope will lead to a new class of cancer drugs, the first designed specifically against a childhood tumor, according to research led by St. Jude Children's Research Hospital scientists.

The chemical is the first small-molecule inhibitor to target the MDMX protein. Excess MDMX is a hallmark of the childhood eye tumor retinoblastoma as well as certain cases of breast, lung, prostate and other cancers. Nationally about 300 new cases of retinoblastoma are identified each year.

The discovery was reported online in advance of the April 2 print edition of the Journal of Biological Chemistry. An overabundance of MDMX or its sister protein, MDM2, can promote tumor progression by binding and suppressing a protein called p53. The role of p53 in normal cells is to induce death in cells that begin the unchecked cell division that is a hallmark of cancer.

MDM2 and MDMX use different mechanisms to disrupt the p53 pathway. There is an emerging scientific consensus that restoring normal p53 function might require shutting down both MDMX and MDM2. A small-molecule inhibitor against MDM2 is already in Phase 1 pharmaceutical industry trials. In this study, St. Jude researchers reported that when the new St. Jude compound, known as SJ-172550, is combined with an MDM2 inhibitor there was a corresponding increase in retinoblastoma cells death.

Michael Dyer, Ph.D., Developmental Neurobiology and the paper's senior author, said several years of detailed chemical studies and additional work are likely needed before SJ-172550 might be ready for human trials.

Evidence suggests SJ-172550 works by binding in a reversible manner to a pocket in the MDMX molecule. With SJ-172550 sitting in the pocket, the p53 protein cannot bind to MDMX, Dyer explained. That makes p53 available to do its job and eliminate tumor cells. About 65 percent of retinoblastoma t
'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
2. Cardiologists and heart surgeons meet for Controversies and Advances conference
3. Lockheed Martin Advances Biometrics Portfolio Through Cooperation Agreement With Cognitec
4. Genetic Engineering & Biotechnology News reports on advances in miRNA
5. Prototype terahertz imager promises biochem advances
6. Science expands Science Signaling, featuring research related to medical advances, and more
7. Analysis of RNA role in spreading disease advances study of damaging plant infections
8. Iowa State-ConocoPhillips collaboration advances 26 research projects in first year
9. Brown to host conference on advances in neurotechnology
10. Latest advances in interventional cardiology for congenital heart disease presented
11. Advances in the field of schizophrenia research: New genetic factors identified
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Advances reported in quest for drugs targeting childhood cancer
(Date:7/8/2015)... -- The consumer products industry for innovative tech ... such as wearables, smart wallets & other smart technology are ... continues to rapidly grow.  Biometrics & Wearable Device Companies in ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ... GPRO ) and Baidu Inc. (NASDAQ: BIDU ) ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... Georgia Institute of Technology have developed a strategy to ... prevent the pollutant from finding its way from a ... a zero emission car, and a transportation system completely ... dioxide emissions from large-scale sources such as power plants ...
... developing is a goal of Raphael Kopan, Ph.D., professor ... School of Medicine. The moss plant (Physcomitrella patens) ... Spencer T. Olin Professor and chair of the WUSTL ... toward that goal. Heres how. The gene ...
... in the media, and recently, in our daily lives, ... is affecting global climate change. Studying just how carbon ... one Northwestern University professor is doing his part by ... associate professor of civil and environmental engineering in the ...
Cached Biology News:Carbon capture strategy could lead to emission-free cars 2Carbon capture strategy could lead to emission-free cars 3Carbon capture strategy could lead to emission-free cars 4Moss protein plays role in Alzheimer's disease 2Moss protein plays role in Alzheimer's disease 3Moss protein plays role in Alzheimer's disease 4Studying rivers for clues to global carbon cycle 2Studying rivers for clues to global carbon cycle 3
(Date:7/29/2015)... 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) announced ... be released on Thursday, August 13, 2015, before the ... management will host a conference call to discuss the ... release outlining the financial results and business update will ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference ...
(Date:7/29/2015)... ... July 29, 2015 , ... Finding gooey or crusty ... quite normal. Although there are a considerable number of terms in popular use to ... post-sleep material is a mixture of mucus, blood cells, skin cells and dust, but ...
(Date:7/29/2015)... ... July 29, 2015 , ... Asymmetrex, LLC founder ... evaluating the full range of capabilities of its unique cache of technologies for ... the day-to-day renewal and repair of normal tissues and organs. This property makes ...
(Date:7/28/2015)... Nev. , July 28, 2015  PDL BioPharma, ... today announced that the Company will release its second ... 30, 2015, on Wednesday, August 5, 2015, after market ... webcast that day at 4:30 p.m. Eastern Time to ... the call will be available via the webcast link ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... Mass., July 23 NxStage Medical,Inc. (Nasdaq: ... today announced ongoing public access to current summary,information ... end-stage,renal-disease (ESRD) who undergo hemodialysis at home on ... to the conventional regimen of therapy,received three times ...
... WILMINGTON, Del., July 23 More than a ... AZN ) to inquire about the,company,s prescription savings ... pharmacists, according to a year-long survey of more ... percent of the patients who called,AstraZeneca,s information center ...
... Future, CAMBRIDGE, Mass., July 23 Genzyme Corporation,(Nasdaq: ... growth in the second,quarter, along with significant progress in ... to approximately $1.171 billion from,$933.4 million in last year,s ... areas of the business., GAAP net income was ...
Cached Biology Technology:NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 2NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 3NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 4NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 5AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 2AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 3Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17
... for Alkaline Phosphatase conjugates. The product ... both the enzyme and the antibody following ... product has been chemically engineered to increase ... shelf life, resistance to various shipping conditions ...
AC input: 50-60 Hz230 V...
... Microarray Slide features an ultra-thin nitrocellulose ... is the first protein microarray slide ... nitrocellulose in a thin film with ... ,The PATH™ Slide can be ...
AC input: 50-60 Hz 115-120 V...
Biology Products: